Alfaro Emely, Dhruva Anand, Langford Dale J, Koetters Theresa, Merriman John D, West Claudia, Dunn Laura B, Paul Steven M, Cooper Bruce, Cataldo Janine, Hamolsky Deborah, Elboim Charles, Kober Kord, Aouizerat Bradley E, Miaskowski Christine
School of Nursing, University of California, San Francisco, CA, USA.
School of Medicine, University of California, San Francisco, CA, USA.
Eur J Oncol Nurs. 2014 Feb;18(1):85-93. doi: 10.1016/j.ejon.2013.08.004. Epub 2013 Sep 5.
To attempt to replicate the associations found in our previous study of patients and family caregivers between interleukin 6 (IL6) and nuclear factor kappa beta 2 (NFKB2) and sleep disturbance and to identify additional genetic associations in a larger sample of patients with breast cancer.
Patients with breast cancer (n = 398) were recruited prior to surgery and followed for six months. Patients completed a self-report measure of sleep disturbance and provided a blood sample for genomic analyses. Growth mixture modeling was used to identify distinct latent classes of patients with higher and lower levels of sleep disturbance.
Patients who were younger and who had higher comorbidity and lower functional status were more likely to be in the high sustained sleep disturbance class. Variations in three cytokine genes (i.e., IL1 receptor 2 (IL1R2), IL13, NFKB2) predicted latent class membership.
Polymorphisms in cytokine genes may partially explain inter-individual variability in sleep disturbance. Determination of high risk phenotypes and associated molecular markers may allow for earlier identification of patients at higher risk for developing sleep disturbance and lead to the development of more targeted clinical interventions.
试图复制我们之前在患者和家庭照顾者中发现的白细胞介素6(IL6)与核因子κB2(NFKB2)之间的关联以及睡眠障碍,并在更大样本的乳腺癌患者中识别其他基因关联。
乳腺癌患者(n = 398)在手术前被招募,并随访6个月。患者完成了一份睡眠障碍的自我报告测量,并提供了一份血样用于基因组分析。生长混合模型用于识别睡眠障碍水平较高和较低的不同潜在类别患者。
年龄较小、合并症较多且功能状态较低的患者更有可能属于高持续性睡眠障碍类别。三种细胞因子基因(即IL1受体2(IL1R2)、IL13、NFKB2)的变异预测了潜在类别归属。
细胞因子基因多态性可能部分解释睡眠障碍的个体间差异。确定高风险表型和相关分子标志物可能有助于更早识别发生睡眠障碍风险较高的患者,并促进更有针对性的临床干预措施的开发。